Intravenous (IV) Ibuprofen Market Report 2026

Intravenous (IV) Ibuprofen Market Overview

• Intravenous (IV) Ibuprofen market size has reached to $9.37 billion in 2025 • Expected to grow to $16.41 billion in 2030 at a compound annual growth rate (CAGR) of 11.8% • Growth Driver: Rising Prevalence Of Pain Disorders Fueling The Growth Of The Market Due To Increasing Demand For Effective Pain Management • Market Trend: Advancing Opioid-Free Pain Management With Innovative Drug Formulations • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Intravenous (IV) Ibuprofen Market?

Intravenous (IV) Ibuprofen is a form of ibuprofen administered directly into the bloodstream through an intravenous route. The primary purpose of intravenous (IV) ibuprofen is to provide rapid pain relief and reduce inflammation or fever, especially in patients who cannot take oral medications. It works by inhibiting the production of prostaglandins, which cause pain and inflammation. Intravenous ibuprofen is commonly used for postoperative pain and acute conditions requiring quick relief. The main product types in the intravenous (IV) ibuprofen market are conventional intravenous (IV) ibuprofen and high-concentration intravenous (IV) ibuprofen. Conventional intravenous (IV) ibuprofen refers to the standard formulation of ibuprofen administered directly into the bloodstream via an IV for pain relief, inflammation reduction, and fever management, typically used in hospital settings for acute or postoperative pain. The available strengths of intravenous ibuprofen include 100 mg, 200 mg, 400 mg, and 800 mg. It is used across different age groups, including pediatrics and adults. The primary applications of IV ibuprofen are for pain, fever, inflammation, and other conditions. Key end-users include hospitals, ambulatory surgical centers, clinics, and other healthcare settings.

What Is The Intravenous (IV) Ibuprofen Market Growth Forecast?

The intravenous (iv) ibuprofen market size is expected to see rapid growth in the next few years. It will grow to $16.41 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to growing demand for opioid-sparing pain management strategies, increasing adoption of iv therapies in ambulatory surgical centers, rising pediatric and geriatric hospitalization rates, expansion of acute care infrastructure, growing preference for fast-onset analgesic treatments. Major trends in the forecast period include growing adoption of iv ibuprofen for postoperative pain management, increasing use of non-opioid analgesics in acute care settings, rising preference for rapid-acting injectable pain therapies, expansion of iv ibuprofen use in pediatric and critical care, increasing availability of high-concentration iv ibuprofen formulations.

Global Intravenous (IV) Ibuprofen Market Segmentation

1) By Product Type: Conventional Intravenous (IV) Ibuprofen, High-Concentration Intravenous (IV) Ibuprofen 2) By Strength: 100 Milligrams (mg), 200 Milligrams (mg), 400 Milligrams (mg), 800 Milligrams (mg) 3) By Age Group: Pediatrics, Adults 4) By Application: Pain, Fever, Inflammation, Other Applications 5) By End-User: Hospitals, Ambulatory Surgical Centers, Clinics, Other End-Users Subsegments: 1) By Conventional Intravenous (IV) Ibuprofen: Pediatric Intravenous (IV) Ibuprofen, Adult Intravenous (IV) Ibuprofen 2) By High-Concentration Intravenous (IV) Ibuprofen: Single-Dose Vial, Multi-Dose Vial

What Is The Driver Of The Intravenous (IV) Ibuprofen Market?

The rising prevalence of pain disorders is expected to propel the growth of the intravenous ibuprofen market going forward. Pain disorders refer to medical conditions characterized by persistent or chronic pain that affects daily functioning, often caused by nerve, musculoskeletal, or inflammatory issues. The rising prevalence of pain disorders is due to the aging population, as older adults are more likely to develop chronic conditions like arthritis, osteoarthritis, and nerve pain, increasing the need for effective pain relief. Intravenous ibuprofen supports pain management by providing fast relief, making it ideal for acute and postoperative pain. It reduces inflammation and enhances patient comfort, improving treatment effectiveness in medical settings. For instance, in January 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, the percentage of individuals aged 16 and older who self-reported having a long-term musculoskeletal condition rose to 18.4% in 2023, up from 17.6% in 2022. Therefore, the rising prevalence of pain disorders is driving the growth of the intravenous ibuprofen market.

Key Players In The Global Intravenous (IV) Ibuprofen Market

Major companies operating in the intravenous (iv) ibuprofen market are Pfizer Inc., Sanofi S.A., Novartis AG, Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., Baxter International, Mylan N.V., Sandoz Group AG, Dr. Reddy's Laboratories, Hikma Pharmaceuticals plc, Eurolife Healthcare Pvt. Ltd., B. Braun Holding GmbH & Co. KG, AFT Pharmaceuticals Ltd, Cumberland Pharmaceuticals Inc., Delex Pharma International Inc., Xgen Pharmaceuticals Djb Inc., Wellona Pharma, Hyloris Pharmaceuticals SA

Global Intravenous (IV) Ibuprofen Market Trends and Insights

Major companies operating in the intravenous ibuprofen market are focusing on developing advanced drug formulations, such as opioid-free analgesics to enhance pain management while minimizing opioid dependency. An opioid-free analgesic is a pain-relieving medication that does not contain opioids without the risk of addiction and opioid-related side effects. For instance, in February 2024, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched COMBOGESIC IV (acetaminophen and ibuprofen) injection in the US, following Food and Drug Administration (FDA) approval in October 2023. This intravenous, opioid-free analgesic is indicated for mild to moderate pain relief and as an adjunct for moderate to severe pain management. By combining two active ingredients with distinct mechanisms, COMBOGESIC IV provides a novel, non-opioid pain management option for healthcare providers.

What Are Latest Mergers And Acquisitions In The Intravenous (IV) Ibuprofen Market?

In May 2024, Halex Istar Industria Farmaceutica SA, a Brazil-based pharmaceutical company, partnered with AFT Pharmaceuticals Ltd. This partnership aims on expanding the distribution of Maxigesic IV (paracetamol + ibuprofen IV) in Brazil, providing effective non-opioid pain management solutions. AFT Pharmaceuticals Ltd is a New Zealand-based pharmaceutical company that specializes in intravenous pain relief.

Regional Outlook

North America was the largest region in the intravenous (IV) ibuprofen market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Intravenous (IV) Ibuprofen Market?

The intravenous (IV) ibuprofen market consists of sales of pediatric intravenous (IV) ibuprofen, intravenous (IV) ibuprofen concentrate and pre-mixed intravenous (IV) ibuprofen bags. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Intravenous (IV) Ibuprofen Market Report 2026?

The intravenous (iv) ibuprofen market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous (iv) ibuprofen industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.